New
HealthMore in Health→
Overcoming RAS Inhibitor Resistance: New Insights for Pancreatic Cancer Combination Therapies
Key Takeaways
- RAS inhibitors like daraxonrasib have shown promise in pancreatic cancer but resistance is a major issue.
- A new study identifies acquired genetic alterations driving resistance, including secondary KRAS mutations, RAS amplification, and downstream pathway activation.
- Combination strategies with MEK or PI3K inhibitors may overcome resistance.
- Liquid biopsies could help monitor resistance and guide treatment adjustments.
DE
DT Editorial Team··via nature.com